Epidemiology and management of refractory lupus nephritis
- PMID: 21565286
- DOI: 10.1016/j.autrev.2011.04.032
Epidemiology and management of refractory lupus nephritis
Abstract
Although the survival of patients with lupus nephritis (LN) has improved considerably in recent years, refractory LN appears in a substantial proportion of patients and, therefore, treatment of LN remains a real challenge today. We will use the term "refractory" LN, for those cases with none or partial response to first-line therapies. In this sense, numerous epidemiological factors, including racial, socioeconomic, histological and serological parameters, may influence treatment response and, therefore, may have an impact on the outcome of renal involvement. Initial conventional therapy will depend somewhat on these epidemiological factors. If this initial therapy fails, fortunately today we have alternative therapies that include the multitarget therapy and the use of biologics. Published evidence about these therapies is presented in this review. Important terms in the management of LN, such as the definition of complete response, partial response, sustained response and renal flare as well as the discrimination of different types of flare, are also discussed here according to the European consensus statement on the terminology used in the management of lupus glomerulonephritis.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Rituximab treatment in lupus nephritis--where do we stand?Lupus. 2013 Apr;22(4):381-9. doi: 10.1177/0961203312471574. Lupus. 2013. PMID: 23553781 Review.
-
The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.Chin Med J (Engl). 1997 Jul;110(7):502-7. Chin Med J (Engl). 1997. PMID: 9594205
-
Therapeutic options for resistant lupus nephritis.Semin Arthritis Rheum. 2006 Oct;36(2):71-81. doi: 10.1016/j.semarthrit.2006.04.008. Epub 2006 Jul 12. Semin Arthritis Rheum. 2006. PMID: 16884971 Review.
-
Major lupus organ involvement: severe lupus nephritis.Lupus. 2010 Oct;19(12):1391-8. doi: 10.1177/0961203310376522. Lupus. 2010. PMID: 20947547 Review.
-
[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Srp Arh Celok Lek. 2002. PMID: 12583309 Serbian.
Cited by
-
Association between immunoglobulin G N-glycosylation and lupus nephritis in female patients with systemic lupus erythematosus: a case-control study.Front Immunol. 2023 Sep 21;14:1257906. doi: 10.3389/fimmu.2023.1257906. eCollection 2023. Front Immunol. 2023. PMID: 37809087 Free PMC article.
-
Clinical research progress of novel biologics for the treatment of lupus nephritis.Clin Exp Med. 2023 Dec;23(8):4153-4162. doi: 10.1007/s10238-023-01143-9. Epub 2023 Jul 22. Clin Exp Med. 2023. PMID: 37481481 Review.
-
Infection profile and risk factors for mortality in patients with end-stage renal disease attributable to systemic lupus erythematosus: a two-center integrated study.J Int Med Res. 2022 Aug;50(8):3000605221118702. doi: 10.1177/03000605221118702. J Int Med Res. 2022. PMID: 35983672 Free PMC article.
-
Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.Front Physiol. 2022 Jul 6;13:930353. doi: 10.3389/fphys.2022.930353. eCollection 2022. Front Physiol. 2022. PMID: 35874527 Free PMC article.
-
New Treatment Options in Lupus Nephritis.Arch Immunol Ther Exp (Warsz). 2022 Mar 17;70(1):11. doi: 10.1007/s00005-022-00647-8. Arch Immunol Ther Exp (Warsz). 2022. PMID: 35298708 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
